Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer

Breast

Volumn 22, Issue 3, 2013, Pages 330-334

  Zhang, Ming ^a   Teng, Xiao dan ^a   Guo, Xin xin ^a   Li, Zhi gao ^a   Han, Ji guang ^a   Yao, Lei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Matrix metalloproteinase; Semiquantitative RT PCR; Tissue inhibitor of metalloproteinase

Indexed keywords

GELATINASE A; GELATINASE B; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

EID: 84877126489     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.08.002     Document Type: Article

References (46)

1. Strnad M., Hrabak-Zerjavic V., Samija M. Epidemiology, prevention and early detection of breast cancer. Breast tumors 2007, 27-32. Medicinska Naklada, Zagreb. 1st ed. M. Samija, S. Juzbasic, V. Separovic, V.D. Vrdoljak (Eds.).
2. Tyczynski J.E., Bray F., Parkin D.M. Breast cancer in Europe. ENCR Cancer Fact Sheets 2002, 2.
3. Liotta L.A., Kohn E. Cancer invasion and metastases. JAMA 1990, 263:1123-1126.
4. Schwartz G.K. Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations. Semin Oncol 1996, 23:316-324.
5. Kohn E.C., Liotta L.A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995, 55:1856-1862.
6. Shim K.N., Jung S.A., Joo Y.H., Yoo K. Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. J Gastroenterol 2007, 42:120-128.
7. Carmeliet P., Moons L., Lijnen R., Baes M., Lemaître V., Tipping P., et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997, 17:439-444.
8. Curran S., Murray G.I. Matrix metalloproteinase in tumour invasion and metastasis. J Pathol 1999, 189:300-308.
9. Monig S.P., Baldus S.E., Hennecken J.K., Spiecker D.B., Grass G., Scheider P.M., et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001, 39:597-602.
10. Passlick B., Sienel W., Seen-Hibler R., Wockel W., Thetter O., Mutschler W., et al. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res 2000, 6:3944-3948.
11. Pyke C., Ralfkiaer E., Tryggvason K., Dano K. Messenger RNA for two type IV collagenase is located in stromal cells in human colon cancer. Am J Pathol 1993, 142:359-365.
12. Stetler-Stevenson W.G., Krutzsch H.C., Liotta L.A. Tissue inhibitors of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989, 264:17374-17378.
13. Parsons S.L., Watson S.A., Brown P.D., Collins H.M., Steele R.J. Matrix metalloproteinases. Br J Surg 1997, 84:160-166.
14. Yamashita K., Azumano I., Mai M., Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 1998, 79:187-194.
15. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997, 89:1260-1270.
16. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
17. Cao J., Sato H., Takino T., Seiki M. The C-terminal region of membrane type matrix metalloproteinase is a functional transmembrane domain required for pro-gelatinase A activation. J Biol Chem 1995, 270:801-805.
18. Seiki M., Yana I. Role of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci 2003, 94:569-574.
19. Zeng Z.S., Cohen A.M., Zhang Z.F., Stetler-Stevenson W., Guillem J.G. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995, 1:899-906.
20. Urbanski S.J., Edwards D.R., Hershfield N., Huchcroft S.A., Shaffer E., Sutherland L., et al. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn Mol Pathol 1993, 2:81-89.
21. Edge S.B., Byrd D.R., Compton C.C. AJCC cancer staging manual 2010, Springer, New York. 7th ed.
22. Bramhall S.R., Neoptolemos J.R., Stamp G.W., Lemoine N.R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997, 182:347-355.
23. Stearns M., Stearns M.E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996, 8:69-75.
24. Sier C.F., Kubben F.J., Ganesh S., Heerding M.M., Griffioen G., Hanemaaijer R., et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996, 74:413-417.
25. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998, 83:1153-1162.
26. Nakopoulou L., Tsirmpa I., Alexandrou P., Louvrou A., Ampela C., Markaki S., et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res Treat 2003, 77:145-155.
27. Jones J.L., Glynn P., Walker R.A. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999, 189:161-168.
28. Hirvonen R., Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma. Breast Cancer Res Treat 2003, 77:85-91.
29. Talvensaari-Mattila A., Paakko P., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003, 89:1270-1275.
30. Yasumitsu H., Miyazaki K., Umenishi F., Koshikawa N., Umeda M. Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells. J Biochem 1992, 111:74-80.
31. Yamagata S., Tanaka R., Ito Y., Shimizu S. Gelatinases of murine metastatic tumor cells. Biochem Biophys Res Commun 1989, 158:228-234.
32. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., et al. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004, 64:1675-1686.
33. Li H.C., Cao D.C., Liu Y., Hou Y., Wu J., Lu J., et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 2004, 88:75-85.
34. Pellikainen J.M., Ropponen K.M., Kataja V.V., Kellokoski J.K., Eskelinen M.J., Kosma V.M. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621-7628.
35. Figueira R.C., Gomes L.R., Neto J.S., Silva F.C., Silva I.D., Sogayar M.C. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:20.
36. Kohrmann A., Kammerer U., Kapp M., Dietl J., Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009, 9:188.
37. Stetler-Stevenson W.G., Liotta L.A., Kleiner D.E. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993, 7:1434-1441.
38. Jian W.G., Davies G., Martin T.A., Parr C., Watkins G., Mason M.D., et al. Targeting matrilysin and its impact on tumor growth in vivo: the potential implications in breast cancer therapy. Clin Cancer Res 2005, 11:6012-6019.
39. Wang F., Reierstad S., Fishman D.A. Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett 2006, 236:292-301.
40. Tetu B., Brisson J., Wang C.S., Lapointe H., Beaudry G., Blanchette C., et al. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis. Breast Cancer Res 2006, 8:R28.
41. Khokha R., Waterhouse P., Yagel S., Lala P.K., Overall C.M., Norton G., et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989, 243:947-950.
42. Nomura H., Fujimoto N., Seiki M., Mai M., Okada Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int J Cancer 1996, 69:9-16.
43. Ree A.H., Florenes V.A., Berg J.P., Maelandsmo G.M., Nesland J.M., Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997, 3:1623-1628.
44. Remacle A., McCarthy K., Noel A., Maguire T., McDermott E., O'Higgins N., et al. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000, 89:118-121.
45. Schrohl A.S., Holten-Andersen M.N., Peters H.A., Look M.P., Meijer-van Gelder M., Klijn J.G.M., et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298.
46. Vizoso F.J., Gonzalez L.O., Corte M.D., Rodriguez J.C., Vazquez J., Lamelas M.L., et al. Study of matrix metalloproteinases and their inhibitors in breast cancer. Br J Cancer 2007, 96:903-911.